Bristol-Myers Squibb Co (BMY) Shares Sold by GSA Capital Partners LLP

Share on StockTwits

GSA Capital Partners LLP decreased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 71.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,500 shares of the biopharmaceutical company’s stock after selling 50,564 shares during the quarter. GSA Capital Partners LLP’s holdings in Bristol-Myers Squibb were worth $1,134,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA lifted its holdings in shares of Bristol-Myers Squibb by 7.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,678,633 shares of the biopharmaceutical company’s stock valued at $422,423,000 after buying an additional 468,740 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 6,283,205 shares of the biopharmaceutical company’s stock valued at $347,713,000 after buying an additional 172,417 shares during the period. Swiss National Bank lifted its holdings in shares of Bristol-Myers Squibb by 2.7% in the second quarter. Swiss National Bank now owns 5,491,170 shares of the biopharmaceutical company’s stock valued at $303,881,000 after buying an additional 146,500 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Bristol-Myers Squibb by 6.7% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,130,236 shares of the biopharmaceutical company’s stock valued at $283,907,000 after buying an additional 320,015 shares during the period. Finally, Parnassus Investments CA lifted its holdings in shares of Bristol-Myers Squibb by 2.9% in the second quarter. Parnassus Investments CA now owns 3,600,000 shares of the biopharmaceutical company’s stock valued at $199,224,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 72.17% of the company’s stock.

A number of brokerages have recently issued reports on BMY. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. Credit Suisse Group boosted their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the stock a “neutral” rating in a research report on Friday, July 27th. BMO Capital Markets reaffirmed a “hold” rating and set a $47.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, June 21st. UBS Group lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 target price on the stock. in a research report on Monday, May 21st. Finally, Jefferies Financial Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $63.11.

NYSE:BMY opened at $60.94 on Friday. The firm has a market cap of $100.03 billion, a P/E ratio of 18.11, a price-to-earnings-growth ratio of 1.54 and a beta of 1.02. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.14. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. Bristol-Myers Squibb’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 earnings per share. equities research analysts predict that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: Growth Stocks

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply